請更新您的瀏覽器

您使用的瀏覽器版本較舊,已不再受支援。建議您更新瀏覽器版本,以獲得最佳使用體驗。

Eng

ChipMOS ADJUSTS CASH DIVIDEND DISTRIBUTION RATIO TO APPROXIMATELY NT$1.23 PER COMMON SHARE OR APPROXIMATELY US$0.82 PER ADS

PR Newswire (美通社)

更新於 2025年06月13日10:59 • 發布於 2025年06月13日10:00 • PR Newswire

HSINCHU, June 13, 2025 /PRNewswire-FirstCall/ -- ChipMOS TECHNOLOGIES INC. ("ChipMOS" or the "Company") (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS), an industry leading provider of outsourced semiconductor assembly and test services ("OSAT"), announced that the Company adjusted the cash dividend distribution ratio from NT$1.20 per common share to approximately NT$1.23 per common share, following the Company's cancellation of treasury shares and the repurchase of shares for transfer to employees, which impacted the total number of the Company's outstanding shares. As a result, the cash dividend per ADS will increase from approximately US$0.80 per ADS to approximately US$0.82 per ADS.

There is no change to any other information disclosed in the original notice filed on May 28, 2025. The dividend was previously approved by the Company's Board and declared on February 25, 2025. The Company submitted a dividend/distribution form to Nasdaq, as notification of the below actions for the Company's American Depositary Shares ("ADRs").

  • Type of Distribution: Cash Dividend
  • Declaration Date: May 27, 2025
  • Ex-Dividend Date: June 27, 2025
  • ADR Dividend Record Date: June 27, 2025
  • ADR Dividend Distribution Date: July 25, 2025
  • ADR books will be closed from June 27 to July 3, 2025
  • The final dividend amount to be distributed in U.S. dollars will be determined by the Depositary, Citibank, N.A., once it receives the distribution from the Company, which is expected to be on July 18, 2025, converts the amount from New Taiwan Dollars into U.S. Dollars and deducts appropriate taxes and fees.

Any questions regarding the dividend distribution should be directed to Citibank, N.A.'s Tiffany Ma (Tel: +1-973-461-5734 or ).

About ChipMOS TECHNOLOGIES INC.:

ChipMOS TECHNOLOGIES INC. ("ChipMOS" or the "Company") (Taiwan Stock Exchange: 8150 and Nasdaq: IMOS) () is an industry leading provider of outsourced semiconductor assembly and test services. With advanced facilities in Hsinchu Science Park, Hsinchu Industrial Park and Southern Taiwan Science Park in Taiwan, ChipMOS is known for its track record of excellence and history of innovation. The Company provides end-to-end assembly and test services to leading fabless semiconductor companies, integrated device manufacturers and independent semiconductor foundries serving virtually all end markets worldwide.

Forward-Looking Statements

This press release may contain certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes,' 'expects,' 'anticipates,' 'projects,' 'intends,' 'should,' 'seeks,' 'estimates,' 'future' or similar expressions or by discussion of, among other things, strategies, goals, plans or intentions. These statements may include financial projections and estimates and their underlying assumptions, statements regarding tariffs, government policies, global trade environments, pricing, plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Actual results may differ materially in the future from those reflected in forward-looking statements contained in this document, due to various factors. Further information regarding these risks, uncertainties and other factors are included in the Company's most recent Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") and in the Company's other filings with the SEC.

Contacts:

In Taiwan

In the U.S.

Jesse Huang

David Pasquale

ChipMOS TECHNOLOGIES INC.

Global IR Partners

+886-6-5052388 ext. 7715

+1-914-337-8801

查看原始文章

TCL Solar Showcases Next-Gen BC Modules at SNEC, Writing the Future of Solar Innovation with Technological Advancements

PR Newswire (美通社)

Bybit Pay Bridges Web3 and Retail Payment in Southeast Asia

PR Newswire (美通社)

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

PR Newswire (美通社)
查看更多
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...